Souhaitez-vous accéder aux communiqués récents ?

USPTO Allows Claims Covering Topical Metformin Eye-Drop Therapy for Retinal Degeneration, Including Age-Related Macular Degeneration Palm Beach Gardens, FL, July 16, 2026 (GLOBE NEWSWIRE) --...

Dublin, July 13, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmology Devices Market Report 2026" has been added to ResearchAndMarkets.com's offering. The ophthalmology devices market has experienced...

Cross Keys Capital is pleased to announce it acted as the exclusive financial adviser to Solinsky Eye Care in its partnership with Refocus Eye Health.

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE...

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...

ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic...

Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials.Veripure is also a quality benchmark,...

BVI today announced the opening of the BVI Experience Hub, a dedicated facility designed to support ophthalmic training and professional development.

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the...